See how research connects peptides to biological targets, signaling pathways, and biological processes.
This tool shows, for each peptide, which biological target the available research points to, how directly that relationship is supported, and how it connects to broader signaling pathways and biological processes. It describes what research suggests about biological mechanisms -- not proven health or treatment outcomes, and not medical advice. See each peptide's full research profile for complete detail, citations, and safety information.
Mechanism research for MitoCore's current product catalog.
Showing 37 of 37 peptides
Evidence legend
Relationship support
Directly supported
Supported indirectly
Inferred from related evidence
Uncertain
Evidence context
Human research
Preclinical research
Human + preclinical research
Review / established literature
Related compound/program context
Evidence context uncertain
Understanding mechanism evidence
This tool describes research into biological targets, signaling pathways, and biological processes -- not proven health or treatment outcomes, and not medical advice. Relationship-support and evidence-context labels describe the type and directness of research available, not proof of safety or effectiveness. See each peptide's full research profile for complete detail, citations, and safety information.
Mechanism profiles
Thymosin Alpha-1
1 mechanism relationship · Supported indirectly · Preclinical research
Thymosin Alpha-1 → TLR9 receptor — Supported indirectlyThymosin Alpha-1's anti-viral and immunomodulatory effects in mice occur through TLR9/MyD88-dependent plasmacytoid dendritic-cell signaling, without demonstrated direct physical binding of Thymosin Alpha-1 to TLR9.
Evidence context
Preclinical research
Thymosin Alpha-1's anti-viral effect against murine cytomegalovirus occurred through TLR9/MyD88-dependent plasmacytoid dendritic-cell activation, confirmed using TLR-deficient mice, leading to IRF7 activation and IFN-alpha/IFN-gamma-dependent effector signaling. A related study found Thymosin Alpha-1-induced dendritic-cell tryptophan catabolism (indoleamine 2,3-dioxygenase pathway) also required TLR9 and type-I interferon receptor signaling. No direct physical binding of exact Thymosin Alpha-1 to TLR9 has been demonstrated; this record does NOT claim Thymosin Alpha-1 is a direct TLR9 ligand and does NOT claim orthosteric TLR9 agonism. Evidence is preclinical (mouse models) only.
Sources
Central Citation Library reference: thymosin-alpha1-bozza-2007-tlr9-myd88-irf7-pmid17804687
Central Citation Library reference: thymosin-alpha1-romani-2006-tlr9-ido-pmid16741252
Central Citation Library reference: thymosin-alpha1-romani-2004-tlr-signaling-pmid14982877
What is established
A target (TLR9 receptor) and pathway family (Immune & Inflammatory Signaling) are documented.
What remains unclear
Specific downstream signaling steps and biological-process associations are not yet documented.
Thymosin Alpha-1's anti-viral effect against murine cytomegalovirus occurred through TLR9/MyD88-dependent plasmacytoid dendritic-cell activation, confirmed using TLR-deficient mice, leading to IRF7 activation and IFN-alpha/IFN-gamma-dependent effector signaling. A related study found Thymosin Alpha-1-induced dendritic-cell tryptophan catabolism (indoleamine 2,3-dioxygenase pathway) also required TLR9 and type-I interferon receptor signaling. No direct physical binding of exact Thymosin Alpha-1 to TLR9 has been demonstrated; this record does NOT claim Thymosin Alpha-1 is a direct TLR9 ligand and does NOT claim orthosteric TLR9 agonism. Evidence is preclinical (mouse models) only.
Key terms
Looking for research areas instead?
Peptide Explorer shows what areas a peptide is researched in. This tool shows how the underlying biology appears to work.
Educational use only. Not medical advice. MitoCore Biosciences does not diagnose, treat, cure, prevent, prescribe, sell peptides, recommend dosing, or provide instructions for human use.
